Claims for Patent: 10,500,208

Summary for Patent: 10,500,208

Title:	Emulsion formulations of aprepitant
Abstract:	Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. Also included are formulations including both aprepitant and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.
Inventor(s):	Ottoboni; Thomas B. (Belmont, CA), Han; Han (Mountain View, CA)
Assignee:	HERON THERAPEUTICS, INC. (San Diego, CA)
Application Number:	15/398,928
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,500,208
Patent Claims:	1. An injectable emulsion comprising: aprepitant; 11 wt/wt % to 15 wt/wt % of an emulsifier; an oil; a co-emulsifier which is an alcohol; a tonicity modifier; a pH modifier; and water; wherein the pH of the emulsion ranges from about 7.5 to 9.0, wherein the emulsion is physically stable. 2. The emulsion according to claim 1, wherein the ratio of the oil to the aprepitant in the emulsion ranges from about 11:1 to 15:1 (wt/wt %). 3. The emulsion according to claim 1, wherein the ratio of the emulsifier to the aprepitant in the emulsion ranges from about 15:1 to 30:1 (wt/wt %). 4. The emulsion according to claim 1, wherein the ratio of emulsifier to oil ranges from about 1:1 to 3:1 (wt/wt %). 5. The emulsion according to claim 4, wherein the emulsifier is a phospholipid. 6. The emulsion according to claim 1, further comprising dexamethasone sodium phosphate, wherein the dexamethasone sodium phosphate is present in the aqueous phase. 7. The emulsion according to claim 1, wherein the emulsifier is an egg lecithin. 8. The emulsion according to claim 1, further comprising a buffer. 9. The emulsion according to claim 1, wherein the pH modifier is sodium oleate. 10. The emulsion according to claim 8, wherein the buffer is Tris buffer. 11. The emulsion according to claim 1, wherein the oil is soybean oil. 12. The emulsion according to claim 1, wherein the alcohol is ethanol. 13. The emulsion according to claim 12, wherein the ethanol is present at less than 10 wt/wt %. 14. A method for preparing a pharmaceutical emulsion according to claim 1 comprising: combining the aprepitant, the emulsifier, and the alcohol with the oil to generate an oil phase; combining water, the Tonicity agent, the pH modifier, and optionally the buffer to generate an aqueous phase; homogenizing, the oil phase with the aqueous phase to generate a coarse emulsion premix; homogenizing the coarse emulsion premix at a pressure between 10,000 and 30,000 psi using a microfluidizer to generate the pharmaceutical emulsion; and sterilizing the pharmaceutical emulsion. 15. The method according to claim 14, wherein homogenizing the coarse emulsion premix comprises 4 to 15 passes through the microfluidizer. 16. The method according to claim 14, wherein the sterilizing comprising passing the pharmaceutical emulsion through a filter having a pore size of about 0.2 microns. 17. The method according to claim 14, further comprising adding a solution of dexamethasone sodium phosphate to the fine emulsion prior to sterile filtration.